Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Subcutaneous Insulin 338 in Healthy Subjects and Type 1 Diabetes
NCT02220296Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2014
- Primary completion
- Mar 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of Insulin 338 in type 1 diabetes mellitus (T1D) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Incidence of adverse events. Started Aug 2014; status: completed.
02
Drugs
Insulin 338
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02220296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220296.